Acadia Pharmaceuticals' CEO on Rebranding and Using AI
Acadia Pharmaceuticals CEO Catherine Owen Adams discusses the company's recent rebrand and expansion into rare disease marketing, as well as its use of AI.
Neurological biotech Acadia Pharmaceuticals has rolled out a rebrand as it seeks to expand into the rare disease space, with AI playing a major role in its marketing strategy.
MM+M spoke with Acadia CEO Catherine Owen Adams on the company's recent rebrand, its expansion into rare disease and how it's using AI throughout commercialization and marketing.
Adams shares her insights on the benefits and challenges of marketing as a smaller biotech and how she's drawing on her marketing background to steer the company into 2026.
Author's summary: Acadia Pharmaceuticals' CEO discusses rebranding and AI use.
More News
- ‘Baby, That’s Show Business’: 4 albums worth crazed consumption
- How Expanding Home Health Care Could Strengthen Maryland’s Health System - MarylandReporter.com
- Understanding the Supreme Court's Interim Intervention in the Waqf Amendments, 2025 | SabrangIndia
- New lunch club for supermarket - The Voice
- End consumerism—start a garden